April 23, 2024Open Access

Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Previous clinical trials presented efficacy and safety of Janus kinase 1 inhibitor upadacitinib through 52 weeks for moderate-to-severe atopic dermatitis (AD).

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Hagino et al. (Tue,) studied this question.

synapsesocial.com/papers/68e6de6eb6db64358765a57c https://doi.org/https://doi.org/10.1080/09546634.2024.2344591

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan2023 · 25 citations
2Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial2019 · 357 citations
3Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 20212022 · 63 citations
4Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis2022 · 1,730 citations
5Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation2023 · 51 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo